Trials / Completed
CompletedNCT04160260
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
A Phase 1 Multi-Center Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Paratek Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omadacycline | Omadacycline: PO Tablets |
Timeline
- Start date
- 2019-11-28
- Primary completion
- 2020-03-23
- Completion
- 2020-04-13
- First posted
- 2019-11-12
- Last updated
- 2021-11-03
- Results posted
- 2021-11-03
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04160260. Inclusion in this directory is not an endorsement.